You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. INTELLIGENT MOUTHGUARD FOR MEASURING HEAD IMPACTS IN YOUTH ATHLETES

    SBC: Sportsguard Laboratories, Inc.            Topic: NICHD

    DESCRIPTION provided by applicant With million young athletes participating in contact sports and between to million concussions endured by young athletes yearly in the US subjective concussion identification increases risk of death time lost from school cognitive decline chronic traumatic encephalopathy CTE depression suicide dementia Alzheimerandapos s and Parkinsona ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. IRE1 alpha inhibitors for type 2 diabetes

    SBC: Optikira, LLC            Topic: 200

    DESCRIPTION provided by applicant The American Diabetes Association has declared type diabetes T D a public health crisis T D begins as a state of compensated insulin resistance frank disease develops when of insulin producing pancreatic islet cells of affected individuals undergo cell death Endoplasmic reticulum ER stress has emerged as a central underlying mechanism that drive ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. IRE1 alpha inhibitors for Retinal Degenerative Diseases

    SBC: Optikira, LLC            Topic: N

    DESCRIPTION provided by applicant Approximately Americans suffer from vision loss due to Retinitis Pigmentosa RP Despite significant progress in elucidating the molecular genetics of RP over the past three decades no disease modifying therapies have been approved There is compelling evidence implicating endoplasmic reticulum ER stress in the pathogenesis of various forms of RP e ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Serious STEM Games To Educate Middle School Students

    SBC: MEADOWLARK SCIENCE AND EDUCATION, LLC            Topic: OD

    DESCRIPTION provided by applicant Improving STEM focused curriculum is a primary objective of the current U S administration and is crucial for ensuring that upcoming generations receive the training and skills necessary to compete in the existing global economy To that end there is an urgent need for additional effective teaching tools able to reach a generation that requires instant access ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne muscular dystrophy is caused by mutations in the dystrophin gene resulting in the loss of the dystrophin glycoprotein complex in skeletal muscle Loss of dystrophin results in reduced sarcolemmal integrity progressive muscle damage and compromised muscle function There is currently no cure and limited treatment options for DMD and all affected child ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. AFARI: A Stylized Adaptive Mobility and Fitness Device for Outdoor Movement

    SBC: R M BEAUMONT CORP            Topic: NIA

    DESCRIPTION provided by applicant Osteoarthritis OA diagnosed in over of the US population is the primary cause of musculoskeletal lower extremity disability Although there is no cure exercise remains the core treatment to manage OA regardless of age comorbidity pain severity or disability Yet many people with this condition do not engage in regular fitness and thus may resort t ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Mouse Stem Cell Research Using the Dracula Pipette

    SBC: GENESEARCH, INC.            Topic: 100

    DESCRIPTION provided by applicant Advanced approaches for genetic or epigenetic modification of embryonic stem ES cells including TALEN ZFN or CRISPR catalyzed genetic modifications or modulation of gene expression via small RNAs synthetic mRNAs or recombinant transcription factors have revolutionized our ability to modify the cells from which novel mouse lines are produced In contra ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Combinatorial RXR-based therapeutics for Alzheimer's disease

    SBC: REXCEPTOR, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): The principle objective of this application is the development of safer and more effective combinatorial therapy for AD. ReXceptor, Inc. is developing new therapeutics for the treatment of AD based on stimulating the physiological clearance mechanisms of soluble forms of A from the brain. Bexarotene is an agonist of the ligand-activated transcription factor, r ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Feasibility of Non-surgical Implant Adjustment

    SBC: Apto Orthopaedics Corportation            Topic: NIAMS

    DESCRIPTION (provided by applicant): While minimally invasive surgery has transformed the practice of surgery, access to implants for removal or alteration still requires surgery which generates risk and high cost. A next-generation approach is non-invasive, where implants are adjusted without an incision. There are clear applications in all fields of surgery, but particulary in orthopaedics wher ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Corneal Endothelial Stem Cells for Treatment of Corneal Endothelial Dystrophies

    SBC: RASHMIVU LLC            Topic: N

    DESCRIPTION provided by applicant Corneal clouding caused by failure of the corneal endothelial deturgesence mechanism affects over million people in the US and well over million people worldwide It is the most common corneal disease and is historically a common cause of blindness Surgical treatment by corneal grafting has been successful when available but is limited by the availabili ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government